Endocrine Abstracts

Aim: To study the indicators of RAAS in patients with DM 2 with chronic heart failure (CHF) and diabetic foot syndrome (DFS).

Material and methods: We observed 75 patients with DM 2, CHF and DFS. Patients were distributed into 3 groups: 1 gr – patients with 2 t and neuroichemic form of DFS and CHF – 22 patients, 2 groups – patients with DM 2 and neuroichemic form of DFS without CHF – 28 patients, 3 groups – patients with CHF without DM 2 –25 patients Patients performed general clinical, biochemical, hormonal, genetic blood tests, as well as an ECG, Echo-ECG, etc. Instrumental studies, as well as statistical methods.

Results: In the study of aldosterone, its increased average values were found in all groups. In patients with CHF, the indicators are reliable than in the group of patients with DM 2. In the group of patients with DM 2 in combination with CHF, the indicators were the highest, reliably different from the indicators of patients with diabetes and unreliable in comparison with the CHF group. Renin levels in groups were significantly higher than the upper limit of the norm lying. However, it should be noted that in the DM 2+CHF group, indicators statistically reliably exceeded the indicators in the first two groups.

Conclusions: Chronic hyperglycemia and RAAS activation are pathogenetic factors that aggravate the course of CHF in patients with DM2. This, in turn, accelerates the development and progression of the late complications of DM 2, worsening the prognosis of both DFS and CHF.